Tag Archives: David Novak

Ziopharm Oncology (ZIOP) Receives a Buy from Raymond James

In a report issued on May 29, David Novak from Raymond James maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report). The company’s shares closed last Thursday at $2.74. According to TipRanks.com, Novak is a 3-star analyst with

Catalyst Biosciences (CBIO) Gets a Buy Rating from Raymond James

Raymond James analyst David Novak maintained a Buy rating on Catalyst Biosciences (CBIO – Research Report) on July 13 and set a price target of $20.00. The company’s shares closed last Wednesday at $5.56. According to TipRanks.com, Novak is a

Raymond James Sticks to Their Buy Rating for Knight Therapeutics (KHTRF)

In a report released today, David Novak from Raymond James maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with a price target of C$10.25. The company’s shares closed last Thursday at $5.12. According to TipRanks.com, Novak is

Raymond James Sticks to Its Buy Rating for Ziopharm Oncology (ZIOP)

In a report released today, David Novak from Raymond James maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report), with a price target of $5.50. The company’s shares closed last Monday at $3.14, close to its 52-week low

Raymond James Remains a Buy on Knight Therapeutics (KHTRF)

Raymond James analyst David Novak maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report) today and set a price target of C$10.25. The company’s shares closed last Monday at $5.85. According to TipRanks.com, Novak is a 4-star analyst

Raymond James Reaffirms Their Buy Rating on Knight Therapeutics (KHTRF)

Raymond James analyst David Novak maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report) today and set a price target of C$10.25. The company’s shares closed last Monday at $6.55, close to its 52-week high of $6.60. According